FindTrial
Sign In

Application of Blood Detection Based on Second Generation Sequencing in Stereotactic Radiotherapy

Application of Blood Detection Based on Second Generation Sequencing in Stereotactic Radiotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015207
Enrollment
Unknown
Registered
2018-03-14
Start date
2018-03-14
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:Stereotactic radiotherapy

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary or metastatic tumors of the eyes; 2. T3-4N0M0 NSCLC; T3-4N0M1; T3-4NX M0-1; 3. T3-4N0M0 NSCLC; T3-4N0M1 (Oligo-metastases); T3-4NX M0-1(Local palliative treatment of symptoms caused by hilar lesions).

Exclusion criteria

Exclusion criteria: 1. Local lesions are not suitable for SRS; 2. Body poor constitution could not accept SRS.

Design outcomes

Primary

MeasureTime frame
ctDNA;—

Countries

China

Contacts

Public ContactHongqing Zhuang

Peking University Third Hospital

yiduzhengmu@163.com+86 010-82264931

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026